here is a link that implies oseltamivir-resistance of H1N1 may be on the increase, as the last Q 2007-march 2008 figure was 16%, which increased to 39% in 2nd Q 2008-13 oct 2008 (worldwide). http://www.who.int/csr/disease/influenza/H1N1200801013.pdf
I was in contact with someone who was later confirmed to have swine flu, so did a little bit of looking for info on oseltamivir and zanamivir.
here's an abstract from another 2009 study on resistance to neuraminidase inhibitors eg oseltamivir zanamivir. unfortunately data seems to be pre-2009, before the outbreak of this year.
The neuraminidase inhibitors (NAIs) are an effective class of antiviral drugs for the treatment of influenza A and B infections. Until recently, only a low prevalence of NAI resistance (<1%) had been detected in circulating viruses. However, surveillance in Europe in late 2007 revealed significant numbers of A(H1N1) influenza strains with a H274Y neuraminidase mutation that were highly resistant to the NAI oseltamivir. We examined 264 A(H1N1) viruses collected in 2008 from South Africa, Oceania and SE Asia for their susceptibility to NAIs oseltamivir, zanamivir and peramivir in a fluorescence-based neuraminidase inhibition assay. Viruses with reduced oseltamivir susceptibility were further analysed by pyrosequencing assay. The frequency of the oseltamivir-resistant H274Y mutant increased significantly after May 2008, resulting in an overall proportion of 64% (168/264) resistance among A(H1N1) strains, although this subtype represented only 11.6% of all isolates received during 2008. H274Y mutant viruses demonstrated on average a 1466-fold reduction in oseltamivir susceptibility and 527-fold reduction in peramivir sensitivity compared to wild-type A(H1N1) viruses. The mutation had no impact on zanamivir susceptibility. Ongoing surveillance is essential to monitor how these strains may spread or persist in the future and to evaluate the effectiveness of treatments against them.
BTA Price at posting:
$1.95 Sentiment: None Disclosure: Held
